Coloplast A/S Sponsored ADR (CLPBY)
(Delayed Data from OTC)
$9.69 USD
+0.04 (0.41%)
Updated Aug 22, 2025 03:59 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLPBY 9.69 +0.04(0.41%)
Will CLPBY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLPBY based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CLPBY
Coloplast price target raised by DKK 10 at RBC Capital
Coloplast price target lowered by DKK 15 at Morgan Stanley
Coloplast A/S (CLPBF) Q3 2025 Earnings Call Transcript
Coloplast A/S Non-GAAP EPS of DKK 3.86, revenue of DKK 6.96B; reaffirms FY outlook
Coloplast: Despite The Drawdown, Still Not A Buy